Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Valtech Cardio: The Israeli start-up named former Boston Scientific executive Bruce H. KenKnight its new president and CEO Feb. 9. KenKnight most recently served as VP-Research and Business Development for Boston Sci's Cardiac Rhythm Management division. Earlier this month, Valtech raised $17.8 million in a Series B financing to aid its development of minimally invasive surgical and transcatheter mitral valve repair and replacement devices

You may also be interested in...



People In Brief

JenaValve, Predictive Biosciences, DexCom among firms with personnel news.

SenoRx names Buhler CEO

Breast cancer device maker appoints John T. Buhler CEO, effective immediately, the firm announces March 16. Buhler, formerly president and chief operating officer, had been acting CEO since former CEO Lloyd H. Malchow went on medical leave in February (1"The Gray Sheet" Feb. 22, 2010). Malchow passed away on March 14

SenoRx names Buhler CEO

Breast cancer device maker appoints John T. Buhler CEO, effective immediately, the firm announces March 16. Buhler, formerly president and chief operating officer, had been acting CEO since former CEO Lloyd H. Malchow went on medical leave in February (1"The Gray Sheet" Feb. 22, 2010). Malchow passed away on March 14

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel